CDMO News
Hikma Pharmaceuticals to Invest $1B in US Manufacturing by 2030
Hikma Pharmaceuticals has unveiled a $1 billion investment plan to enhance its US-based manufacturing and research operations by 2030. The new investment phase, branded America Leans on Hikma: Quality Medicines Manufactured in the USA, will enhance Hikma’s established domestic capabilities to develop,
1 July 2025
Stay ahead of trends and best practices
